ProQR Therapeutics Past Earnings Performance
Past criteria checks 0/6
ProQR Therapeutics's earnings have been declining at an average annual rate of -10.8%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 4.2% per year.
Key information
-10.8%
Earnings growth rate
10.7%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | 4.2% |
| Return on equity | -99.7% |
| Net Margin | -1,355.9% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ProQR Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 5 | -65 | 19 | 51 |
| 30 Sep 22 | 4 | -72 | 20 | 51 |
| 30 Jun 22 | 4 | -63 | 20 | 47 |
| 31 Mar 22 | 4 | -63 | 19 | 47 |
| 31 Dec 21 | 2 | -62 | 17 | 42 |
| 30 Sep 21 | 2 | -57 | 16 | 38 |
| 30 Jun 21 | 2 | -55 | 14 | 35 |
| 31 Mar 21 | 1 | -43 | 13 | 34 |
| 31 Dec 20 | 1 | -47 | 14 | 38 |
| 30 Sep 20 | 1 | -52 | 14 | 44 |
| 30 Jun 20 | 1 | -51 | 14 | 46 |
| 31 Mar 20 | 2 | -58 | 14 | 47 |
| 31 Dec 19 | 2 | -56 | 13 | 46 |
| 30 Sep 19 | 3 | -51 | 14 | 42 |
| 30 Jun 19 | 5 | -45 | 13 | 37 |
| 31 Mar 19 | 6 | -40 | 13 | 34 |
| 31 Dec 18 | 6 | -37 | 13 | 30 |
| 30 Sep 18 | 4 | -35 | 11 | 28 |
| 30 Jun 18 | 2 | -40 | 11 | 29 |
| 31 Mar 18 | 1 | -44 | 11 | 31 |
| 31 Dec 17 | 1 | -44 | 11 | 31 |
| 30 Sep 17 | 1 | -41 | 10 | 31 |
| 30 Jun 17 | 1 | -41 | 9 | 32 |
| 31 Mar 17 | 1 | -39 | 9 | 33 |
| 31 Dec 16 | 2 | -39 | 9 | 32 |
| 30 Sep 16 | 3 | -36 | 9 | 30 |
| 30 Jun 16 | 3 | -33 | 9 | 28 |
Quality Earnings: PRQR N is currently unprofitable.
Growing Profit Margin: PRQR N is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRQR N is unprofitable, and losses have increased over the past 5 years at a rate of 10.8% per year.
Accelerating Growth: Unable to compare PRQR N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRQR N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).
Return on Equity
High ROE: PRQR N has a negative Return on Equity (-99.66%), as it is currently unprofitable.